DataMeds AI Provides Update on Corexa Health's Pharmacy Division
Rhea-AI Summary
DataMeds AI (NASDAQ:MEDS) reported multiple developments at its Corexa Health pharmacy division, positioning Corexa Pharmacy as a key growth driver for the second half of 2026. July 2026 revenue exceeded $600,000, which the company said stabilizes an annualized run rate above $7 million.
Corexa Pharmacy registered with TrumpRx to offer patients oral and injectable GLP-1 agonist drugs, including Eli Lilly's Foundayo and Novo Nordisk's oral Wegovy, with certain oral options available for as little as $149 out-of-pocket. Companion medical foods Forzet and Galectovid, and dietary supplement Tollovid, manufactured by Tollo Health, are now available alongside other nutraceuticals.
The company launched online store CorexaRx.com/Store and integrated it into the Health Lives Here app, initially introduced for former NFL players via NFL Alumni Health, enabling telemedicine visits, GLP-1 prescriptions, product refills, and health data monitoring. According to DataMeds AI, a public launch of the Health Lives Here app is expected in September 2026 with a staged state-by-state rollout starting in North Carolina.
Positive
- July 2026 revenue exceeded $600,000, stabilizing an annualized run rate above $7 million for Corexa Pharmacy
- TrumpRx registration enables access to oral GLP-1 agonist drugs for as little as $149 out-of-pocket
- Health Lives Here app integration links CorexaRx.com/Store with telemedicine, prescriptions, refills and health data monitoring
- Product portfolio expansion adds Forzet, Galectovid, Tollovid, other dietary supplements and non-GLP-1 drugs
Negative
- None.
News Explained
Corexa Pharmacy plans to expand beyond GLP-1 drugs to medicines for other conditions, which would broaden its dispensing portfolio, but the release presents that expansion as preparation rather than a completed rollout.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 10 | Division renaming | Positive | -19.6% | Subsidiary renaming under Corexa Health preceded a negative 24-hour price reaction. |
| Aug 05 | Media appearance | Positive | -11.7% | Fox Business appearance introducing Health Lives Here preceded a negative 24-hour price reaction. |
| Jul 31 | Product launch | Positive | -4.4% | Corexa Pharmacy launched Tollo Health products before a negative 24-hour price reaction. |
| Jul 29 | License expansion | Positive | -15.5% | PharmacyChain license expansion with Datavault AI preceded a negative 24-hour price reaction. |
| Jul 29 | License expansion | Positive | -15.5% | Expanded healthcare blockchain license preceded a negative 24-hour price reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The five tag-specific AI events all recorded negative 24-hour reactions, averaging -13.34%.
Key Terms
glp-1 agonist medical
medical food medical
telemedicine medical
run rate financial
smart contracts technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
GLP-1 agonist drugs now available
Integration of online store CorexaRx.com into Health Lives Here app now complete
Medical foods Forzet™ & Galectovid™, and dietary supplement Tollovid® now available
Revenue stabilized above
$600,000 for July 2026 amid rebranding as pharmacy prepares to expand through the launch of Health Lives Here app with NFL Alumni Health
TAMPA, FL / ACCESS Newswire / August 12, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the compliant delivery of healthcare and monetization of health data by market participants, today provided an update on the Company's pharmaceuticals-focused subsidiary Corexa Health's pharmacy division Corexa Pharmacy. Corexa Pharmacy recently achieved several qualitative and quantitative milestones that position it to be the centerpiece of Company growth in the 2nd half of 2026.
Recent Milestones
Registration with TrumpRx to be able to offer patients access to oral GLP-1 agonist drugs, such as Eli Lilly's Foundayo® and Novo Nordisk's oral Wegovy, for as little as
$149 out of pocket costs. Injectable GLP-1 agonist drugs are also now available.Availability of GLP-1 agonist companion medical food Forzet®, manufactured by Tollo Health, LLC, to complement patients' use of GLP-1 agonist drugs for the dietary management of muscle loss associated with weight loss therapies.
Launch of online store CorexaRx.com/Store.
Integration of CorexaRx.com/Store into the Health Lives Here app (via Apple App Store and Google Play) that was recently introduced at the 2026 Pro Football Hall of Fame Game initially exclusively for former NFL players allowing patients to conduct a telemedicine visit and be prescribed and/or refill a GLP-1 agonist drug as well as Forzet, and monitor health data over time while on therapy. The Health Lives Here app is expected to launch to the public in September 2026, with a staged state by state rollout beginning in North Carolina.
Availability of Tollo Health, LLC medical food Galectovid™ and dietary supplement Tollovid® targeting customers with acute and chronic viral infections.
Availability of other dietary supplements to allow customers to order their suite of nutraceuticals from Corexa Pharmacy alongside their medications.
Portfolio expansion to non-GLP-1 agonist pharmaceutical drugs in order to dispense drugs to patients prescribed GLP-1 agonist drugs, as well as medications for other conditions.
July 2026 revenue exceeded
$600,000 , stabilizing Corexa Pharmacy's run rate above$7 million annually as the Company prepares to benefit from the initiation of a former NFL player-led influencer campaign to drive downloads, physician visits, GLP-1 agonist drug prescriptions and sales of companion product Forzet through the Health Lives Here app, marketed together with NFL Alumni Health
DataMEDS interim co-CEO Gerald Commissiong commented, "We are very pleased with the stabilization of revenue in Corexa Pharmacy, which was recently rebranded from its prior name Wellgistics Pharmacy. With that rebrand now complete and significant infrastructure improvements and new proprietary sales channels on the horizon supported by high profile marketing, we believe that we are poised to start driving significant growth through the pharmacy as a result of our proprietary telemedicine platform becoming more broadly available, initially focusing on GLP-1 users. The Health Lives Here app provides a unique window to monitor patients' health, and we believe that physicians will see tremendous value in using our technology platform and novel products to help improve patient outcomes."
About DataMeds AI, Inc.
DataMeds AI, Inc. (formerly Wellgistics Health) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding: the Company's non-binding letter of intent to acquire a controlling interest in Tollo Health, LLC, and the anticipated timing, structure, terms and completion of that transaction; the Company's proposed acquisition of the QOLPOM intellectual property portfolio and the anticipated development and integration of that technology; the Company's license of, and plans to integrate, healthcare delivery intellectual property from DataVault AI Inc.; the Company's plans to expand into telemedicine and diagnostic laboratory services; the Company's proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors; the satisfaction or waiver of closing conditions applicable to any of the foregoing; the receipt of stockholder approval and any other required approvals; the Company's anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the market for Long COVID products and related treatment approaches; the Company's ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the Company's technology platforms, strategic relationships and business combinations; the Company's capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations; and other risks described in the Company's filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
DataMeds AI Media Contact
James Lambert, Vice President
Rubenstein Public Relations
Phone: 212.805.3024
Email: jlambert@rubensteinpr.com
DataMeds AI Investor Contact
Investor Relations: IR@wellgisticshealth.com
SOURCE: DataMeds AI, Inc.
View the original press release on ACCESS Newswire